123 related articles for article (PubMed ID: 24720539)
1. Hypoxia selects for a quiescent, CML stem/leukemia initiating-like population dependent on CBP/catenin transcription.
Kida A; Kahn M
Curr Mol Pharmacol; 2013 Nov; 6(3):204-10. PubMed ID: 24720539
[TBL] [Abstract][Full Text] [Related]
2. CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.
Zhao Y; Masiello D; McMillian M; Nguyen C; Wu Y; Melendez E; Smbatyan G; Kida A; He Y; Teo JL; Kahn M
Oncogene; 2016 Jul; 35(28):3705-17. PubMed ID: 26657156
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
Gang EJ; Hsieh YT; Pham J; Zhao Y; Nguyen C; Huantes S; Park E; Naing K; Klemm L; Swaminathan S; Conway EM; Pelus LM; Crispino J; Mullighan CG; McMillan M; Müschen M; Kahn M; Kim YM
Oncogene; 2014 Apr; 33(17):2169-78. PubMed ID: 23728349
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
6. The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells.
Kim YM; Ma H; Oehler VG; Gang EJ; Nguyen C; Masiello D; Liu H; Zhao Y; Radich J; Kahn M
Curr Cancer Drug Targets; 2011 Feb; 11(2):213-25. PubMed ID: 21158719
[TBL] [Abstract][Full Text] [Related]
7. Volatile anesthetics sevoflurane targets leukemia stem/progenitor cells via Wnt/β-catenin inhibition.
Ruan X; Jiang W; Cheng P; Huang L; Li X; He Y; Mai M; Tan Z
Biomed Pharmacother; 2018 Nov; 107():1294-1301. PubMed ID: 30257344
[TBL] [Abstract][Full Text] [Related]
8. Nuclear receptor/Wnt beta-catenin interactions are regulated via differential CBP/p300 coactivator usage.
Ono M; Lai KKY; Wu K; Nguyen C; Lin DP; Murali R; Kahn M
PLoS One; 2018; 13(7):e0200714. PubMed ID: 30020971
[TBL] [Abstract][Full Text] [Related]
9. CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.
Bordonaro M; Lazarova DL
World J Gastroenterol; 2015 Jul; 21(27):8238-48. PubMed ID: 26217075
[TBL] [Abstract][Full Text] [Related]
10. Determination of the Role of CBP- and p300-Mediated Wnt Signaling on Colonic Cells.
Bordonaro M; Lazarova DL
JMIR Res Protoc; 2016 May; 5(2):e66. PubMed ID: 27177606
[TBL] [Abstract][Full Text] [Related]
11. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
12. The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner.
Wiese M; Walther N; Diederichs C; Schill F; Monecke S; Salinas G; Sturm D; Pfister SM; Dressel R; Johnsen SA; Kramm CM
Oncotarget; 2017 Apr; 8(16):27300-27313. PubMed ID: 28460484
[TBL] [Abstract][Full Text] [Related]
13. Specific Direct Small Molecule p300/β-Catenin Antagonists Maintain Stem Cell Potency.
Higuchi Y; Nguyen C; Yasuda SY; McMillan M; Hasegawa K; Kahn M
Curr Mol Pharmacol; 2016; 9(3):272-279. PubMed ID: 26008738
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/β-catenin signaling.
Li Y; Hu J; Song H; Wu T
Biochem Biophys Res Commun; 2018 Nov; 505(3):858-864. PubMed ID: 30301525
[TBL] [Abstract][Full Text] [Related]
15. Convergence of Canonical and Non-Canonical Wnt Signal: Differential Kat3 Coactivator Usage.
Lai KKY; Nguyen C; Lee KS; Lee A; Lin DP; Teo JL; Kahn M
Curr Mol Pharmacol; 2019; 12(3):167-183. PubMed ID: 30836930
[TBL] [Abstract][Full Text] [Related]
16. The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators.
Teo JL; Kahn M
Adv Drug Deliv Rev; 2010 Sep; 62(12):1149-55. PubMed ID: 20920541
[TBL] [Abstract][Full Text] [Related]
17. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
[TBL] [Abstract][Full Text] [Related]
18. Oxygen regulates proliferation of neural stem cells through Wnt/β-catenin signalling.
Braunschweig L; Meyer AK; Wagenführ L; Storch A
Mol Cell Neurosci; 2015 Jul; 67():84-92. PubMed ID: 26079803
[TBL] [Abstract][Full Text] [Related]
19. The Mode of Stem Cell Division Is Dependent on the Differential Interaction of β-Catenin with the Kat3 Coactivators CBP or p300.
Lukaszewicz AI; Nguyen C; Melendez E; Lin DP; Teo JL; Lai KKY; Huttner WB; Shi SH; Kahn M
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31324005
[TBL] [Abstract][Full Text] [Related]
20. [Research Advance on Classic Wnt Pathway in Chronic Myelogenous Leukemia--Review].
Cao ZR; Chen XP; Hu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):350-353. PubMed ID: 32027302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
